Andrew Dunn

@AndrewE_Dunn

Pharma and biotech reporter for Say hello: adunn@businessinsider.com

Washington, DC
Vrijeme pridruživanja: ožujak 2015.
Rođen/a 11. srpnja

Medijski sadržaj

  1. 31. sij

    Simple — yet stunning — graphic to see. # of confirmed cases of coronavirus in China, per daily situation reports from WHO. Just under 25,000 cases if you add suspected cases in China.

  2. 13. sij

    Roche, Illumina have inked a 15-year deal on next-gen sequencing in oncology. Worth remembering Roche walked away from a $6.2B buyout offer for in 2012.

  3. 8. sij

    As 2020 has started out quiet on the M&A front, interesting new research on January's disproportional importance for M&A in biopharma. The month has made up 29% of all deal value, 19% of all deals in typical year from 2015-2019, per Evercore analysts. Jan. deals in last 5 yrs:

    Prikaži ovu nit
  4. 3. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    Great Q - I asked Alnylam's a little over a year ago the same thing. He sees it as biotechs take risks, pharmas manage them. For me, I do tend to see it more about size than science. When I think pharma, I think broad commercial portfolios + profits

  5. 17. pro 2019.

    "The three waves of Sangamo" Interesting to see the third wave does not include gene therapy.

    Prikaži ovu nit
  6. 17. pro 2019.

    unveils 3 new preclinical programs on R&D day, including a PKU gene therapy:

    Prikaži ovu nit
  7. 12. pro 2019.

    They say bring the energy, electrify the audience on TV hits My interpretation:

  8. 9. pro 2019.

    CEO Paul Hudson will outline plan tomorrow prioritizing these six experimental therapies

    Prikaži ovu nit
  9. 9. pro 2019.

    Pharma of the Year: Case in point, check out this transformation of their core business over the past few years:

    Prikaži ovu nit
  10. 19. stu 2019.

    Last but not least, well-deserved shout-outs to Industry Dive's UI engineer for designing this series and adding some amazing data visualization and graphic components. And killed it with custom illustrations for each article, like this one (11/11)

    Prikaži ovu nit
  11. 15. stu 2019.

    Acting FDA commissioner Brett Giroir says "hope has never been higher" for SCD community. "The opportunity before us in the coming months and years is profound and historic," Giroir says.

    Prikaži ovu nit
  12. 15. stu 2019.
    Prikaži ovu nit
  13. 12. stu 2019.

    Endpoints' writes on 's plans to lay off about 200 of the 584 workers in Riom, France Merck's workforce has shrunk in the past decade despite great financial success. Made this chart last month after news of 500 US layoffs:

  14. 5. stu 2019.

    continues Epidiolex launch with quarter-over-quarter growth. Q3 sales of $86.1M, making it $188M YTD.

  15. 5. stu 2019.

    This individual patient-level variability figures to be a major part of 's argument:

    Prikaži ovu nit
  16. 1. stu 2019.
    Odgovor korisniku/ci

    WaPo going with the speak-it-into-existence style

  17. 30. lis 2019.

    Fascinating panel starting on antibiotic resistance and the lack of pharma engagement. Featuring , NICE’s Nick Crabb, ’s Mark Feinberg, US Adult CF Foundation’s Ella Balasa, Wellcome Trust’s Jeremy Knox and ’s Jenelle Krishnamoorthy

    Prikaži ovu nit
  18. 24. lis 2019.

    Top BioPharma employers list out from Science: top 3 is and Here’s the top 20:

    Prikaži ovu nit
  19. 18. lis 2019.

    A tale of big pharma over the past decade: Merck stock up ~125% Headcount down 31% from 100k to 69k More layoff plans announced today for :

  20. 11. lis 2019.

    Q3 report from : average list price dropped by 0.6% in Q3, but 125 list prices were hiked in the quarter Here's the org's long-term list price index and full report here:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·